EUVIMEDEUVIMED entdecken
Systematische Übersicht

Fungal Infections Associated With TNF ‐Inhibitors: A 20‐Year of a Systematic Review Fungal Infections and TNF ‐Inhibitors

Layala Stefane de Paula Barbosa, Marina Miranda Ely, Túlio Máximo Salomé, Gleyce Hellen de Almeida de Souza, Daniel Assis Santos iD, Rafael Wesley Bastos, Luana Rossato

Mycoses · 2025-03 · 68 (3)

DOI: 10.1111/myc.70040 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Mycoses, online erschienen am 10.03.2025. Verfasst von Layala Stefane de Paula Barbosa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Ciências da Saúde (FCS), Rodovia Dourados/Itahum, Federal University of Grande Dourados (UFGD), Dourados, Mato Grosso do Sul, Brazil. Hauptthemen laut MEDLINE: Mycoses, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TNF‐α inhibitors, including infliximab, adalimumab and etanercept, are used to treat various inflammatory diseases, such as arthritis, psoriasis and ankylosing spondylitis. However, these treatments may predispose patients to fungal infections, including histoplasmosis, candidiasis and aspergillosis. In this study, we systematically reviewed case reports to critically examine the correlations between anti‐TNF‐α therapies and the occurrence of invasive and superficial fungal infections. Infliximab was the most commonly used TNF‐α inhibitor (50.65%). The highest number of fungal infections during anti‐TNF34 α therapy was reported in the USA (84.25%). The conditions treated primarily included rheumatoid arthritis. A total of 517 invasive fungal infections were identified, including histoplasmosis, invasive candidiasis and aspergillosis, with histoplasmosis being the most common. Most studies were conducted in higher‐income countries, highlighting the critical lack of research on the use of immunobiologicals in relation to fungal diseases in African countries, which requires further attention. Logistic regression analysis revealed significant associations between adalimumab use and increased risks of candidiasis, coccidioidomycosis, onychomycosis and pityriasis versicolor. For etanercept, significant associations were found with aspergillosis, coccidioidomycosis, cryptococcosis, dermatophytosis, invasive candidiasis, pityriasis versicolor and onychomycosis. Infliximab use was significantly associated with coccidioidomycosis, onychomycosis, aspergillosis, cryptococcosis, histoplasmosis and invasive candidiasis. The data presented in this study clearly demonstrate an association between the use of TNF‐α inhibitors and an increased risk of fungal infections. It is imperative that healthcare professionals maintain a high level of vigilance when managing patients on these medications. Regular monitoring and proactive management strategies are essential to mitigate risks and ensure patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MycosesTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alphaHumansAdalimumabArthritis, RheumatoidEtanerceptInfliximabInvasive Fungal Infections

Stichwörter der Autor:innen

Candida spp.aspergillosiscandidemiacryptococcosisdeep fungal infectionimmunodeficiencypityriasis versicolorsystemic infection

Substanzen

AdalimumabEtanerceptInfliximabTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Faculdade de Ciências da Saúde (FCS), Rodovia Dourados/Itahum, Federal University of Grande Dourados (UFGD), Dourados, Mato Grosso do Sul, Brazil.
  • Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • National Institute of Science and Technology in Human Pathogenic Fungi, Ribeirão Preto, São Paulo, Brazil.
  • Laboratório de Uso Comum, Centro de Biociências, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.

ORCID-Profile: Daniel Assis Santos

Zitieren

APA

Barbosa, L. S. P., Ely, M. M., Salomé, T. M., de Almeida de Souza, G. H., Santos, D. A., Bastos, R. W., & Rossato, L. (2025). Fungal Infections Associated With TNF ‐Inhibitors: A 20‐Year of a Systematic Review Fungal Infections and TNF ‐Inhibitors. Mycoses, 68(3). https://doi.org/10.1111/myc.70040

Vancouver

Barbosa LSP, Ely MM, Salomé TM, de Almeida de Souza GH, Santos DA, Bastos RW, et al. Fungal Infections Associated With TNF ‐Inhibitors: A 20‐Year of a Systematic Review Fungal Infections and TNF ‐Inhibitors. Mycoses. 2025;68(3). doi:10.1111/myc.70040

BibTeX
@article{Barbosa2025,
  author = {Barbosa, Layala Stefane de Paula and Ely, Marina Miranda and Salomé, Túlio Máximo and de Almeida de Souza, Gleyce Hellen and Santos, Daniel Assis and Bastos, Rafael Wesley and Rossato, Luana},
  title = {Fungal Infections Associated With TNF ‐Inhibitors: A 20‐Year of a Systematic Review Fungal Infections and TNF ‐Inhibitors},
  journal = {Mycoses},
  year = {2025},
  volume = {68},
  number = {3},
  doi = {10.1111/myc.70040}
}
Kostenlos starten →